Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Resistance to a common antibiotic combo may not be as deadly as feared. A large Danish study found that patients with piperacillin-tazobactam (TZP)-resistant bloodstream infections caused by E. coli or K. pneumoniae did not face significantly higher 30-day mortality than those with susceptible infections — once underlying health factors were accounted for. The findings challenge assumptions about antibiotic resistance and patient outcomes.
A major Danish cohort study is pushing back on a widely held assumption: that resistance to piperacillin-tazobactam (TZP), a commonly used antibiotic combination, automatically leads to worse survival in bloodstream infections (BSIs). Analyzing over 34,000 patients with E. coli or K. pneumoniae BSIs between 2018 and 2024, researchers found that while TZP-resistant infections appeared deadlier on the surface, that difference disappeared once patient health factors were properly accounted for.
The key insight? Sicker patients are more likely to both harbor resistant bacteria and die — making resistance look like the culprit when it may not be. After adjusting for comorbidities, hospitalization history, and other clinical factors, the mortality risk between resistant and susceptible infections was essentially the same.
Key Takeaways:
Why it matters: TZP use is rising as a go-to empirical treatment for BSIs, and so is resistance to it. This study suggests that resistance alone may not be driving mortality, pointing clinicians toward a more nuanced view of antibiotic stewardship and treatment decisions.
